Since becoming only the second Alzheimer鈥檚-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD...
May 19, 2025 | MPP 鈥�21 Asif Khan in Policy Magazine critically examines the long-awaited rollout of the Canada Disability Benefit (CDB). While the federal government has promoted the CDB as a...
March 10, 2025 |聽Norman Hillmer, a Slater Family Visiting Scholar spoke on 鈥淐anada as the 51st聽State? A History and a Reckoning,鈥� at the Laurier Centre for the Study of Canadian History, Wilfrid...
April 7, 2025 | Taylor Owen and Helen A. Hayes wrote an opinion piece arguing that Canada鈥檚 failure to regulate its digital space is no longer just a tech policy issue鈥攊t鈥檚 a national security...
RSS